HGG-18. Long-term efficacy and safety of larotrectinib in paediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system (CNS) tumours

INTRODUCTION: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in various tumours. Larotrectinib, a highly selective TRK inhibitor, demonstrated an objective response rate (ORR) of 75% across 206 evaluable patients with various non-primary CNS cancers (Hong et al, ASCO...

Descripción completa

Detalles Bibliográficos
Autores principales: Nysom, Karsten, Doz, François, Geoerger, Birgit, Øra, Ingrid, Perreault, Sebastien, Norenberg, Ricarda, Fellous, Marc, De La Cuesta, Esther, Laetsch, Theodore W, van Tilburg, Cornelis M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
High Grade Glioma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165410/
http://dx.doi.org/10.1093/neuonc/noac079.233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165410/
http://dx.doi.org/10.1093/neuonc/noac079.233

Ejemplares similares